PMC:7784786 / 3027-4305 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"138","span":{"begin":163,"end":166},"obj":"Gene"},{"id":"139","span":{"begin":336,"end":341},"obj":"Gene"},{"id":"140","span":{"begin":346,"end":350},"obj":"Gene"},{"id":"141","span":{"begin":461,"end":466},"obj":"Gene"},{"id":"142","span":{"begin":468,"end":472},"obj":"Gene"},{"id":"143","span":{"begin":477,"end":482},"obj":"Gene"},{"id":"144","span":{"begin":765,"end":769},"obj":"Gene"},{"id":"145","span":{"begin":771,"end":776},"obj":"Gene"},{"id":"146","span":{"begin":781,"end":786},"obj":"Gene"},{"id":"147","span":{"begin":157,"end":162},"obj":"Species"},{"id":"148","span":{"begin":552,"end":560},"obj":"Species"},{"id":"149","span":{"begin":647,"end":655},"obj":"Species"},{"id":"150","span":{"begin":1091,"end":1099},"obj":"Species"},{"id":"151","span":{"begin":1246,"end":1254},"obj":"Species"},{"id":"152","span":{"begin":0,"end":10},"obj":"Chemical"},{"id":"153","span":{"begin":690,"end":700},"obj":"Chemical"},{"id":"154","span":{"begin":981,"end":991},"obj":"Chemical"},{"id":"155","span":{"begin":585,"end":594},"obj":"Disease"},{"id":"156","span":{"begin":668,"end":677},"obj":"Disease"},{"id":"157","span":{"begin":1082,"end":1090},"obj":"Disease"}],"attributes":[{"id":"A138","pred":"tao:has_database_id","subj":"138","obj":"Gene:923"},{"id":"A139","pred":"tao:has_database_id","subj":"139","obj":"Gene:214"},{"id":"A140","pred":"tao:has_database_id","subj":"140","obj":"Gene:3558"},{"id":"A141","pred":"tao:has_database_id","subj":"141","obj":"Gene:3458"},{"id":"A142","pred":"tao:has_database_id","subj":"142","obj":"Gene:3569"},{"id":"A143","pred":"tao:has_database_id","subj":"143","obj":"Gene:7124"},{"id":"A144","pred":"tao:has_database_id","subj":"144","obj":"Gene:3569"},{"id":"A145","pred":"tao:has_database_id","subj":"145","obj":"Gene:7124"},{"id":"A146","pred":"tao:has_database_id","subj":"146","obj":"Gene:3458"},{"id":"A147","pred":"tao:has_database_id","subj":"147","obj":"Tax:9606"},{"id":"A148","pred":"tao:has_database_id","subj":"148","obj":"Tax:9606"},{"id":"A149","pred":"tao:has_database_id","subj":"149","obj":"Tax:9606"},{"id":"A150","pred":"tao:has_database_id","subj":"150","obj":"Tax:9606"},{"id":"A151","pred":"tao:has_database_id","subj":"151","obj":"Tax:9606"},{"id":"A152","pred":"tao:has_database_id","subj":"152","obj":"MESH:C000597346"},{"id":"A153","pred":"tao:has_database_id","subj":"153","obj":"MESH:C000597346"},{"id":"A154","pred":"tao:has_database_id","subj":"154","obj":"MESH:C000597346"},{"id":"A155","pred":"tao:has_database_id","subj":"155","obj":"MESH:D011565"},{"id":"A156","pred":"tao:has_database_id","subj":"156","obj":"MESH:D011565"},{"id":"A157","pred":"tao:has_database_id","subj":"157","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Itolizumab is a humanized monoclonal antibody developed at the Center of Molecular Immunology, in Cuba, that recognizes a region in the distal domain of the human CD6 [10,11]. The antibody reduces the expression of the intracellular proteins involved in activation and inhibits the proliferation of T cells, even in the presence of the ALCAM and IL-2 [10–12]. The effect is associated with the reduction of the secretion of pro-inflammatory cytokines including IFN-γ, IL-6 and TNF-α [13,14]. The antibody has demonstrated to be safe and efficacious in patients with moderate to severe psoriasis [15,16]. Studies from blood and tissue samples from patients with severe psoriasis showed that itolizumab reduces the proliferation of T cells and serum concentration of IL-6, TNF-α and IFN-γ [13–16]. A significant reduction of the inflammatory pattern was also observed in the tissue. On account of its well proven effect on T-cell activation and proinflammatory cytokines production, itolizumab was included as part of a Cuban expanded access protocol in critical, severe and moderate COVID-19 patients with high risk of aggravation. The study will be published soon (manuscript accepted) and here we describe in detail the outcome of three initial patients receiving the antibody."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T7","span":{"begin":585,"end":594},"obj":"Phenotype"},{"id":"T8","span":{"begin":668,"end":677},"obj":"Phenotype"}],"attributes":[{"id":"A7","pred":"hp_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/HP_0003765"},{"id":"A8","pred":"hp_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/HP_0003765"}],"text":"Itolizumab is a humanized monoclonal antibody developed at the Center of Molecular Immunology, in Cuba, that recognizes a region in the distal domain of the human CD6 [10,11]. The antibody reduces the expression of the intracellular proteins involved in activation and inhibits the proliferation of T cells, even in the presence of the ALCAM and IL-2 [10–12]. The effect is associated with the reduction of the secretion of pro-inflammatory cytokines including IFN-γ, IL-6 and TNF-α [13,14]. The antibody has demonstrated to be safe and efficacious in patients with moderate to severe psoriasis [15,16]. Studies from blood and tissue samples from patients with severe psoriasis showed that itolizumab reduces the proliferation of T cells and serum concentration of IL-6, TNF-α and IFN-γ [13–16]. A significant reduction of the inflammatory pattern was also observed in the tissue. On account of its well proven effect on T-cell activation and proinflammatory cytokines production, itolizumab was included as part of a Cuban expanded access protocol in critical, severe and moderate COVID-19 patients with high risk of aggravation. The study will be published soon (manuscript accepted) and here we describe in detail the outcome of three initial patients receiving the antibody."}

{"project":"LitCovid-sentences","denotations":[{"id":"T29","span":{"begin":0,"end":175},"obj":"Sentence"},{"id":"T30","span":{"begin":176,"end":359},"obj":"Sentence"},{"id":"T31","span":{"begin":360,"end":491},"obj":"Sentence"},{"id":"T32","span":{"begin":492,"end":603},"obj":"Sentence"},{"id":"T33","span":{"begin":604,"end":795},"obj":"Sentence"},{"id":"T34","span":{"begin":796,"end":880},"obj":"Sentence"},{"id":"T35","span":{"begin":881,"end":1130},"obj":"Sentence"},{"id":"T36","span":{"begin":1131,"end":1278},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Itolizumab is a humanized monoclonal antibody developed at the Center of Molecular Immunology, in Cuba, that recognizes a region in the distal domain of the human CD6 [10,11]. The antibody reduces the expression of the intracellular proteins involved in activation and inhibits the proliferation of T cells, even in the presence of the ALCAM and IL-2 [10–12]. The effect is associated with the reduction of the secretion of pro-inflammatory cytokines including IFN-γ, IL-6 and TNF-α [13,14]. The antibody has demonstrated to be safe and efficacious in patients with moderate to severe psoriasis [15,16]. Studies from blood and tissue samples from patients with severe psoriasis showed that itolizumab reduces the proliferation of T cells and serum concentration of IL-6, TNF-α and IFN-γ [13–16]. A significant reduction of the inflammatory pattern was also observed in the tissue. On account of its well proven effect on T-cell activation and proinflammatory cytokines production, itolizumab was included as part of a Cuban expanded access protocol in critical, severe and moderate COVID-19 patients with high risk of aggravation. The study will be published soon (manuscript accepted) and here we describe in detail the outcome of three initial patients receiving the antibody."}